Taysha Gene Therapies, Inc.

TSHA· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$5.78-1.37%

2026-08-03

Financials

Valuation Metrics

Taysha Gene Therapies, Inc.'s Market Cap is $1.66B. At end of 2025 it was $1.76B. Ranked #2188 of 3,112 in US market (top 70%), #859 of 1,445 on NASDAQ (top 59%), #156 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 58%) by Market Cap.

Investment Metrics(as of 2026-08-03)

Metric	Value	Rank
Size
Market Cap	$1.66B	US#2,188/3,112 Sec#156/269
Revenue	$7M	US#2,929/3,112 Sec#185/269
Net Income	$-130M	US—/3,112 Sec—/269
Total Assets	$300M	US#2,898/3,112 Sec#211/269
Net Assets	$212M	US#2,720/3,112 Sec#194/269
Value
P/B	7.84x	US#2,479/3,112 Sec#188/269
P/S	222.32x	US#2,926/3,112 Sec#190/269
FCF Yield	-6.94%	US—/3,112 Sec—/269
Profitability
ROE	-61.28%	US#2,776/3,112 Sec#189/269
ROA	-43.24%	US#2,939/3,112 Sec#200/269
Op. Margin	-1774.37%	US#2,931/3,112 Sec#181/269
Revenue Growth	-100.00%	US#2,948/3,112 Sec#190/269
Financial Health
Debt Ratio	41.71%	US#474/3,112 Sec#131/269
Total Debt	$18M	US#2,712/3,112 Sec#184/269
FCF	$-115M	US#2,612/3,112 Sec#161/269
Cash	$277M	US#1,483/3,112 Sec#88/269
Current Ratio	14.04x	US#171/3,112 Sec#56/269
Performance
1Y Return	119.77%	US#250/3,112 Sec#68/269
1M Return	-11.49%	US#2,674/3,112 Sec#181/269
From 52W High	-20.82%	US#1,765/3,112 Sec#113/269
1Y MDD	-31.13%	US#1,466/3,112 Sec#92/269
Trading
Volume	1,915,601 shares	US#922/3,112 Sec#84/269
Trading Value	$11M	US#2,287/3,112 Sec#180/269
Per Share
EPS	$-0.34	US—/3,112 Sec—/269
BPS	$0.77	US#2,653/3,112 Sec#210/269